http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2741003-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f22b6a9bcf63b8ebe7cd9fdf87e0e7f1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-145 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145 |
| filingDate | 2020-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aafb2bb37ef26eadc2d866c599c4326e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc00c434a8df0745516d10a8b5649162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc9fd04f5aa984f08b0a8befcab750e4 |
| publicationDate | 2021-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2741003-C1 |
| titleOfInvention | Method for production of tetravalent subunit vaccine against influenza without adjuvants |
| abstract | FIELD: medicine; pharmaceuticals. n SUBSTANCE: invention refers to medicine and pharmaceutics, namely to a method for producing a tetravalent subunit vaccine without adjuvants for influenza prevention, according to which a) obtaining four mono-vaccines containing one of serotypes of influenza viruses H1N1, H3N2, B (Victoria line) or B (Yamagata line), wherein to obtain monovaccine producing a virus-containing allantoic liquid, then inactivated with beta-propiolactone and purified and concentrated by microfiltration, ultrafiltration and two cycles of ultracentrifugation in a sucrose density gradient; destroying the virions in the obtained purified viral concentrate by successive treatment with Triton X-100 and TDTAB; sub-virion structures are removed by ultracentrifugation and microfiltration and detergents by ultrafiltration and concentration of the obtained purified supernatant with subsequent purification by hydrophobic chromatography using ExpandedBedAdsorption technology; diluting the concentrate with a phosphate buffer solution containing Triton X-100 to obtain a monovaccine; b) combining the four monovaccines into a single dosage form. n EFFECT: technical result consists in improvement of purification and immunogenicity of tetravalent subunit vaccine without adjuvants during its production in accordance with the declared method. n 4 cl, 14 dwg, 2 tbl, 11 ex |
| priorityDate | 2020-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 61.